6 Result(s)
-
Article
Open AccessSingle dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
Junin virus (JUNV) is a pathogen of biodefense importance due to its potential for aerosol transmission and mortality rates reaching 30%. Currently, there are no JUNV vaccines licensed by the United States Foo...
-
Article
Open AccessA single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in us...
-
Article
Establishment of an African green monkey model for COVID-19 and protection against re-infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an unprecedented global pandemic of COVID-19. Animal models are urgently needed to study the pathogenesis of COVID-19 and to scre...
-
Article
Post-exposure treatments for Ebola and Marburg virus infections
The filoviruses, Ebola virus and Marburg virus, cause lethal haemorrhagic fever in humans and non-human primates (NHPs), and there are currently no licensed va...
-
Article
Erratum: Post-exposure treatments for Ebola and Marburg virus infections
Nature Reviews Drug Discovery (2018); 10.1038/nrd.2017.251 The discussion of the phase II trial of TKM-130803 reported in reference 156 has been revised to correct inaccuracies in the original text.
-
Article
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
Thomas Geisbert and colleagues show that a cocktail of monoclonal antibodies protects cynomolgus monkeys from lethal Lassa fever virus infection, including when administration is delayed by more than a week af...
